Cell culture media are growth substances and nutrients for cells or microorganisms, required in every biopharmaceutical manufacturing process.
As part of the agreement, SSB will sell and market Lonza’s media and buffers used in the manufacture of protein-based therapeutics and vaccines while Lonza will continue to develop, manufacture and operate logistics for the products.
The global collaboration also allows joint development of new products as well as sale of ready to use cell culture media under both brands under a co-branding arrangement.
SSB said it will acquire Lonza’s commercial team of nearly 15 media specialists.
SSB board of directors member Reinhard Vogt said with the collaboration SSB will now add array of media and buffers to product offering.
"In 2 the manufacture of biologicals, our customers will benefit from obtaining fully integrated single-use solutions for their entire cell culture process all from a single source," Vogt added.
Lonza Bioscience COO Lukas Utiger said, "For Lonza this agreement provides great upside potential as it will allow us to capture additional value from our Media Business in the form of additional revenue leading to higher capacity utilization."
The companies have not disclosed additional contractual conditions.